ArticleFrontiers in cardiovascular medicine2025
Endovascular repair of abdominal aortic aneurysm-related type II endoleak: a multicenter study on the possibility of further intervention.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We aimed to analyze the risk factors associated with Type II endoleak (T2EL) requiring reintervention after endovascular aneurysm repair (EVAR) for multicenter abdominal aortic aneurysms. Methods: A retrospective analysis was conducted on data from 614 patients with abdominal aortic aneurysms who underwent elective EVAR at three centers (Tianjin Medical University General Hospital, Affiliated Hospital of Inner Mongolia Medical University, Shanxi Provincial People's Hospital) from January 2017 to December 2021. After applying exclusion criteria, 375 patients were included in the study, with 50 patients in the T2EL-related reintervention group and 325 patients in the non-T2EL group. Single-factor and multiple-factor logistic analyses were used to identify high-risk factors, and ROC curve analysis was performed to determine the risk thresholds for mesenteric artery diameter, number of lumbar arteries, maximum aneurysm diameter, and proportion of intraluminal thrombus volume. Results: The rate of T2EL-related reintervention among the 375 patients was 13.33% (50/375). Single-factor analysis indicated that age, hypertension, maximum aneurysm diameter, proportion of intraluminal thrombus, diameter of inferior mesenteric artery (IMA), and number of patent lumbar arteries (LA) were risk factors for T2EL-related reintervention. Multiple-factor logistic analysis identified maximum aneurysm diameter, proportion of thrombus, IMA diameter, and number of patent LA as the main influencing factors for T2EL-related reintervention after EVAR. Significant risk factors for reintervention were maximum aneurysm diameter (OR = 1.043, 95% CI 1.015-1.072, Conclusion: Cases with identified risk factors are considered to have a higher risk of T2EL-related reintervention after EVAR. Exceeding the new risk thresholds may indicate a higher likelihood of T2EL-related reintervention after EVAR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.